Fidelity Investments’s Aimmune Therapeutics AIMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-584
Closed -$20K 4473
2020
Q3
$20K Sell
584
-2,305,625
-100% -$49.1M ﹤0.01% 3060
2020
Q2
$38.5M Sell
2,306,209
-249,722
-10% -$4.24M ﹤0.01% 1274
2020
Q1
$36.9M Sell
2,555,931
-320,352
-11% -$8.19M 0.01% 1146
2019
Q4
$96.3M Buy
2,876,283
+463,698
+19% +$13M 0.01% 926
2019
Q3
$50.5M Buy
2,412,585
+1,003
+0% +$20.5K 0.01% 1160
2019
Q2
$50.2M Sell
2,411,582
-323,001
-12% -$6.65M 0.01% 1214
2019
Q1
$61.1M Buy
2,734,583
+635,362
+30% +$15M 0.01% 1128
2018
Q4
$50.2M Sell
2,099,221
-11,260
-0.5% -$291K 0.01% 1139
2018
Q3
$57.6M Sell
2,110,481
-413,890
-16% -$11.7M 0.01% 1195
2018
Q2
$67.9M Sell
2,524,371
-288,900
-10% -$8.84M 0.01% 1134
2018
Q1
$89.5M Buy
2,813,271
+243,231
+9% +$8.56M 0.01% 1033
2017
Q4
$97.2M Sell
2,570,040
-378,845
-13% -$12.2M 0.01% 1007
2017
Q3
$73.1M Sell
2,948,885
-67,171
-2% -$1.45M 0.01% 1120
2017
Q2
$62M Sell
3,016,056
-479,103
-14% -$9.14M 0.01% 1198
2017
Q1
$75.9M Sell
3,495,159
-1,453,868
-29% -$29.8M 0.01% 1104
2016
Q4
$101M Buy
4,949,027
+37,200
+0.8% +$760K 0.01% 987
2016
Q3
$73.7M Buy
4,911,827
+35,260
+0.7% +$476K 0.01% 1128
2016
Q2
$52.8M Sell
4,876,567
-280,410
-5% -$3.81M 0.01% 1252
2016
Q1
$69.9M Sell
5,156,977
-1,180,437
-19% -$18.4M 0.01% 1117
2015
Q4
$117M Buy
6,337,414
+250,179
+4% +$4.63M 0.02% 896
2015
Q3
$154M Buy
+6,087,235
New +$142M 0.02% 760

Fidelity Investments's AIMT Position: Q4 2020 in Review

Fidelity Investments sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 584 shares — an estimated $20K sold.

Fidelity Investments first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $154M in Q3 2015. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Fidelity Investments reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Fidelity Investments sold 584 Aimmune Therapeutics shares in Q4 2020, an estimated $20K.
  • Fidelity Investments first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
  • Fidelity Investments's Aimmune Therapeutics position peaked at $154M in Q3 2015.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Fidelity Investments's 13F filing for Q4 2020, filed 8 Feb 2021.